Given co-expression of hnRNPA1 and the BET protein BRD4 in human thyroid and pancreatic tumors, and the favorable safety profiles of Quercetin and BET inhibitors, our study provides a rationale for pursuing this combination therapy in advanced cancer patients. This evidence concerns the gene BRD4 and cancer.